Skip to content
Cover: a researcher reviewing patent documents beside a microscope

EHL Bio's patents and research: how to read them properly

A patent is not an approved medicine

Quick answer

EHL Bio publishes its patent and research list to demonstrate technical capability, spanning a fat harvesting/SVF separation kit, 15-PGDH inhibitor applications for atopic dermatitis and rheumatoid arthritis, and a three-dimensional low-oxygen culture method for producing conditioned media. The key distinction for readers: a patent protects an invention; it does not mean the product's efficacy is proven or that it is approved for treatment.

Key facts

Notable patent
15-PGDH inhibitor (2012, no. 10-1172638)
Device patent
Fat harvesting & SVF kit (2016)
Culture method
3D low-oxygen culture (2018)
Japan certification
CPC, 2017
Most advanced product
ADSTEM (phase 2)

The patents filed and granted

Listed patents include a novel thiazolidinedione derivative (filed 2012) that inhibits 15-PGDH, relevant to cardiovascular, gastrointestinal and renal disease and hair loss prevention; a fat harvesting and SVF separation kit (2016); a cosmetic composition from stem cell conditioned media and its production method (2018); and 15-PGDH inhibitor patents for atopic dermatitis and rheumatoid arthritis.

The development ladder for a cell drug

The cell drug pathway runs candidate → preclinical → phase 1 (safety) → phase 2 (dose and efficacy signal) → phase 3 (confirmatory efficacy) → registration. EHL's most advanced asset, ADSTEM, sits at phase 2.

Key regulatory milestones

Regulatory milestones the company cites include Japanese CPC certification in 2017, Korea's first human cell handling licence, and being the country's first certified cell processing facility.

How to read research claims without being misled

Practical advice: when an advert cites patents or research counts, ask what stage the product you would actually receive is at, how many humans have been studied, and what its legal status is in the country where you would be treated.

Frequently asked questions

  • Does holding a patent mean it is safe?

    No. Patents assess novelty and applicability, not clinical safety or efficacy.

  • Where can I verify trial status?

    Search Korea's clinical trial registry (CRIS) and ClinicalTrials.gov by product or company name.

  • Does phase 2 mean it is usable?

    Not yet. Phase 2 finds dose and efficacy signals; phase 3 and registration are required before general clinical use.

  • What should I ask the hospital first?

    Ask the exact product name, its research stage, cell dose per session, the lot release test report, total cost, and the post-treatment follow-up plan.

Share this page

Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.

Back to categories

Related topics: EHL hospital & lab

See all in this category